Theresa Janke has over 15 years of clinical research and operations, alliance and program management, and business operations start-up experience in the biopharmaceutical industry, including work in immunotherapy, gene therapy, oncolytic virus therapy, and medical devices. She was a founding member of the management team at 4D Molecular Therapeutics, a leader in targeted AAV gene therapy, and is co-founder and board member of IGNITE Immunotherapy. At 4DMT, Theresa serves as Senior Vice President, Business Operations & Alliance Management. At IGNITE Immunotherapy, Theresa brings her extensive business operations and alliance management expertise to drive company operations and initiatives that are core to our mission.

Theresa started her career in clinical research in medical devices with Allergan and Abbott.
She later expanded into oncology therapeutics R&D, serving as Director of Clinical Operations and Project Management at Jennerex Biotherapeutics, a pioneer in intravenous oncolytic virus immunotherapy. There she led the strategic planning and execution of the first randomized Phase 2 oncolytic virus immunotherapy trial with JX-594 (aka Pexa-Vec, an engineered oncolytic vaccinia virus). This trial was the first in history to report a statistically significant survival benefit for an oncolytic virus vaccine (published in Nature Medicine, 2013). She was responsible for managing all aspects of clinical operations across numerous Phase 1-3 clinical trial sites in the US, Canada, South Korea, Taiwan, China, Germany and France. In addition to directing clinical operations, Theresa led numerous international corporate clinical development alliances in Europe and Asia.

Theresa graduated from the University of California, Santa Barbara in 1996 with a Bachelor of Science (Biology & Neuropsychology).

At Celgene, as Director of Clinical R&D Strategy and Alliances, Theresa worked closely with the SVP of Clinical R&D for hematology-oncology; she led the development of Clinical Research and Development (CR&D)-Regulatory 5-year integrated Clinical Development Plans (CDP) for each disease area within the hematology-oncology group.

Theresa graduated from the University of California, Santa Barbara in 1996 with a Bachelor of Science in Biopsychology. She also holds professional certificates from UC Berkeley in the area of clinical project management.

Theresa’s relevant scientific publications include:

  • Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nature Medicine. 2013.
  • Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma; preclinical and clinical demonstration of combination efficacy. Molecular Therapy. 2011.